Some Coronavirus Researchers Are Running Low on Masks

A large-scale shortage of respirators and face shields threatens progress in some labs that are currently trying to ramp up their studies of SARS-CoV-2.

Written byKatarina Zimmer
| 7 min read
n95 mask coronavirus covid-19 sars-cov-2 ppe personal protective equipment face shield respirator virology research lab scientists

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

ABOVE: © ISTOCK.COM, LILIBOAS

Virologist Benjamin tenOever and his colleagues at the Icahn School of Medicine at Mount Sinai in New York are racing to find drugs that work against SARS-CoV-2. The lab, which until recently focused on a large-scale research project studying transmission of influenza virus between ferrets, is now using the animals to see if already-approved drugs show promise in stalling coronavirus replication or improving symptoms of infected animals. Should any treatment show signs of working, it’ll be considered for use in patients battling COVID-19.

Work with the live virus has to be conducted in biosafety level-3 (BSL-3) labs, carefully regulated facilities where workers are required to wear a suite of gear to protect themselves and people who come into contact with them. Facial protection typically comes in two forms: the preferred choice is a powered air-purifying respirator (PAPR)—a reusable device that pumps filtered air into a face ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • katya katarina zimmer

    After a year teaching an algorithm to differentiate between the echolocation calls of different bat species, Katarina decided she was simply too greedy to focus on one field of science and wanted to write about all of them. Following an internship with The Scientist in 2017, she’s been happily freelancing for a number of publications, covering everything from climate change to oncology. Katarina is a news correspondent for The Scientist and contributes occasional features to the magazine. Find her on Twitter @katarinazimmer and read her work on her website.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies